Lorad of Danbury, CT, will show its latest developments in bothscreen-film and digital mammography in its RSNA booth. On theconventional side, Lorad will introduce M-IV, its newest mammographyplatform and successor to M-III (SCAN 10/11/95). M-IV's high
Lorad of Danbury, CT, will show its latest developments in bothscreen-film and digital mammography in its RSNA booth. On theconventional side, Lorad will introduce M-IV, its newest mammographyplatform and successor to M-III (SCAN 10/11/95).
M-IV's high transmission cellular grid system (HTC) improvescontrast in screen-film mammography at an equal or lower radiationdose than conventional systems, according to Hal Kirshner, presidentof Lorad and ThermoTrex Medical. It should prove particularlyuseful for imaging patients with dense breasts, Kirshner said.HTC will be available as an option on M-IV units.
Lorad will also reveal its latest work in full-view digital mammography.The company will show patient images acquired with a system beingused by Dr. Laurie Fajardo at the University of Virginia.
In addition, the company has adapted its StereoLoc prone digitalbreast biopsy technology for its upright mammography systems.Lorad will also display a line of radiographic equipment beingdeveloped for the firm by Bennett X-Ray, its new sister company.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.